Durect nosedives on psoriasis trial results

3 January 2020

Californian biotech Durect Corporation (Nasdaq: DRRX) lost almost a third of its value in the stock market on Thursday after the company announced disappointing results from its study of DUR-928 in mild to moderate plaque psoriasis.

During the Phase IIa trial, 22 patients applied DUR-928 topically to the plaque on one arm and placebo to a similar plaque on the other arm daily for 28 days.

DUR-928 did not demonstrate a benefit over placebo based on investigator's global assessment, which was the scoring system for the primary analysis, or in any of the secondary analyses.

Despite the bad news from this trial, the picture looks brighter for DUR-928 in other indications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK